Targeted drug trial seeks to control tumors driven by specific genetic flaw
NCT ID NCT05023655
Summary
This study tested whether the drug tazemetostat could help control advanced solid tumors that have a specific genetic change called an ARID1A mutation. The drug was given to adult patients whose cancer had progressed after standard treatments. The goal was to see if blocking a related protein (EZH2) could slow or shrink these specific tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States
Conditions
Explore the condition pages connected to this study.